Results 21 to 30 of about 11,769,643 (158)

Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects [PDF]

Journal of Psychoactive Drugs, 2020
Rafael Lancelotta, Alan K Davis
exaly   +2 more sources

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety [PDF]

American Journal of Drug and Alcohol Abuse, 2019
Roland R. Griffiths, Joseph Barsuglia, Rafael Lancelotta   +2 more
exaly   +2 more sources

Corrigendum: A Single Dose of 5-MeO-DMT Stimulates Cell Proliferation, Neuronal Survivability, Morphological and Functional Changes in Adult Mice Ventral Dentate Gyrus [PDF]

Frontiers in Molecular Neuroscience, 2019
Rafael Vitor Lima da Cruz, Thiago C. Moulin, Lyvia Lintzmaier Petiz, Richardson N. Leão, Richardson N. Leão   +4 more
doaj   +2 more sources

5-MeO-DMT: Potential Use of Psychedelic-Induced Experiences in the Treatment of Psychological Disorders. [PDF]

ACS Med Chem Lett, 2021
Kargbo RB.
europepmc   +4 more sources

A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers

Frontiers in Pharmacology, 2021
5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a tryptamine with ultra-rapid onset and short duration of psychedelic effects. Prospective studies for other tryptamines have suggested beneficial effects on mental health outcomes.
Johannes Reckweg, Natasha L. Mason, Cees van Leeuwen, Stefan W. Toennes, Theis H. Terwey, Johannes G. Ramaekers   +5 more
doaj   +1 more source

5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. [PDF]

Neuropsychopharmacology, 2023
Serotonergic psychedelics are gaining increasing interest as potential therapeutics for a range of mental illnesses. Compounds with short-lived subjective effects may be clinically useful because dosing time would be reduced, which may improve patient access.
Jefferson SJ, Gregg I, Dibbs M, Liao C, Wu H, Davoudian PA, Woodburn SC, Wehrle PH, Sprouse JS, Sherwood AM, Kaye AP, Pittenger C, Kwan AC.   +12 more
europepmc   +3 more sources

Infoveillance and Critical Analysis of the Systematically Reviewed Literature on Dimethyltryptamine and the “God Molecule”

Pharmaceuticals, 2023
Aboriginals of Latin America have used DMT (N,N-dimethyltryptamine) in ritualistic ceremonies for centuries. Nevertheless, there are limited data on web users’ interest concerning DMT.
Ahmed Al-Imam, Marek A. Motyka, Beata Hoffmann, Anita Magowska, Michal Michalak   +4 more
doaj   +1 more source

Author Correction: 5-MeO-DMT induces sleep-like LFP spectral signatures in the hippocampus and prefrontal cortex of awake rats [PDF]

Scientific Reports
Annie C. Souza, Bryan C. Souza, Arthur França, Marzieh Moradi, Nicholy C. Souza, Katarina E. Leão, Adriano B. L. Tort, Richardson N. Leão, Vítor Lopes-dos-Santos, Sidarta Ribeiro   +9 more
doaj   +2 more sources

Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence

Frontiers in Psychiatry, 2022
BackgroundThe psychedelic 5-MeO-DMT has shown clinical potential due to its short duration and ability to induce mystical experiences. However, a phenomenon known as “reactivations” (similar to “flashbacks”) is a poorly understood and frequently reported
Ana María Ortiz Bernal, Charles L. Raison, Rafael L. Lancelotta, Alan K. Davis, Alan K. Davis   +4 more
doaj   +1 more source

A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers

European Psychiatry, 2022
Introduction 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a tryptamine with ultra-rapid onset and short duration of psychedelic effects. Prospective studies for other tryptamines have suggested beneficial effects on mental health outcomes ...
J. Reckweg, N. Mason, C. Van Leeuwen, S. Tönnes, T. Terwey, J. Ramaekers   +5 more
doaj   +1 more source